PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Gauges a company's financial stability and solvency. Value investors pay close attention to leverage and liquidity risk, ensuring the company has enough cushion to withstand downturns without impairing shareholder value.
0.12
Positive D/E while TRVN shows negative equity. John Neff would examine our competitive advantages in a challenging market.
0.76
Higher net debt at 1.1-1.25x TRVN's 0.62. Bruce Berkowitz would look for hidden assets justifying this higher leverage.
-7.24
Both companies show negative coverage. Martin Whitman would investigate if industry distress creates special situation opportunities.
1.25
Current ratio 50-75% of TRVN's 1.78. Bill Ackman would demand clear path to liquidity improvement.
No Data
No Data available this quarter, please select a different quarter.